Skip to main content

Prof Reich on the Results of BE-VIVID and BE-READY, Two Phase 3 Clinical Trials on Bimekizumab, an IL-17A/IL-17F Inhibitor

Kristian Reich, MD, PhD, discusses the results of two phase 3 clinical trials, BE-READY and BE-VIVID, that tested the efficacy and safety of bimekizumab, a novel IL-17A/IL-17F inhibitor. Dr Reich is affiliated with the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation® Center in Germany.

Back to Top